ArticleProbiotics and antimicrobial proteins2026
Gut Limosilactobacillus reuteri-secreted Components Mitigate Susceptibility to Radiation by Alleviating Oxidative Stress in the Intestinal Epithelium.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Radiotherapy is the most effective method to eliminate several types of cancer; however, radiation-induced intestinal damage, such as epithelial cell apoptosis, remains a perennial problem. The study revealed that the feces of mice surviving exposure to 7.5 Gy ionizing radiation (IR) originally harbored higher levels of Lacticaseibacillus casei, Lactobacillus salivarius (LS), and Limosilactobacillus reuteri (LR) than those in the commensal bacteria of dead mice. While mice pre-inoculated with LS and LR for 8 weeks showed protective efficacy against 7.5 Gy IR, mice pretreated with LR-Secreted Components (LR-SCs) for 7 days demonstrated lesser epithelial damage and susceptibility to high IR doses than those of LS-SC treated mice. LR-SC treatment also regulated the increased levels of IR-induced cellular reactive oxygen species levels in intestinal epithelial cells. In summary, LR-SCs are potential prophylactic agents to alleviate the side effects of radiotherapy in patients with cancer.
Indexed as
Identifiers
42645781What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.